Orbimed Advisors LLC Alector, Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$21.65 - $39.49 $13.2 Million - $24.1 Million	-611,478 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $23.9 Million - $35.9 Million	-1,613,835 Reduced 72.52%	611,478 $12.3 Million
Q4 2020 Feb 16, 2021	SELL	$9.4 - $16.7 $4.7 Million - $8.35 Million	-500,000 Reduced 18.35%	2,225,313 $33.6 Million
Q3 2020 Nov 16, 2020	SELL	$10.54 - $24.96 $34.3 Million - $81.1 Million	-3,250,009 Reduced 54.39%	2,725,313 $28.7 Million
Q2 2020 Aug 14, 2020	SELL	$21.87 - $33.11 $51.4 Million - $77.9 Million	-2,352,369 Reduced 28.25%	5,975,322 $146 Million
Q1 2020 May 15, 2020	SELL	$16.25 - $35.28 $43.2 Million - $93.9 Million	-2,660,253 Reduced 24.21%	8,327,691 $201 Million
Q4 2019 Feb 14, 2020	SELL	$14.17 - $20.3 $21.9 Million - $31.4 Million	-1,544,385 Reduced 12.32%	10,987,944 $189 Million
Q3 2019 Nov 14, 2019	SELL	$14.42 - $22.2 $9.37 Million - $14.4 Million	-650,000 Reduced 4.93%	12,532,329 $181 Million
Q1 2019 May 15, 2019	BUY	$15.97 - $22.5 $211 Million - $297 Million	13,182,329 New	13,182,329 $247 Million

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $147M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.